CA2272373A1 - Preparation de threo-methylphenidate enrichi en un enantiomere - Google Patents

Preparation de threo-methylphenidate enrichi en un enantiomere Download PDF

Info

Publication number
CA2272373A1
CA2272373A1 CA002272373A CA2272373A CA2272373A1 CA 2272373 A1 CA2272373 A1 CA 2272373A1 CA 002272373 A CA002272373 A CA 002272373A CA 2272373 A CA2272373 A CA 2272373A CA 2272373 A1 CA2272373 A1 CA 2272373A1
Authority
CA
Canada
Prior art keywords
process according
threo
methylphenidate
acid
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002272373A
Other languages
English (en)
Inventor
Susan Faulconbridge
Marianne Langston
Hooshang Shahriari Zavareh
Graham Robert Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9625972.6A external-priority patent/GB9625972D0/en
Priority claimed from GBGB9712298.0A external-priority patent/GB9712298D0/en
Application filed by Individual filed Critical Individual
Publication of CA2272373A1 publication Critical patent/CA2272373A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé pour augmenter l'excédent d'un énantiomère dans un mélange d'énantiomères déjà enrichi en un énantiomère, faisant appel à un sel d'addition du thréo-méthylphénidate avec un acide, l'acide étant achiral. Ce procédé consiste à effectuer une cristallisation dans un solvant ou à effectuer une dissolution partielle dans ce solvant, et si nécessaire, à éliminer tout agent de résolution qui pourrait être présent. Ce procédé peut être précédé par une résolution biocatalytique du thréo-méthylphénidate ou de l'acide ritalinique racémique
CA002272373A 1996-12-13 1997-12-11 Preparation de threo-methylphenidate enrichi en un enantiomere Abandoned CA2272373A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9625972.6A GB9625972D0 (en) 1996-12-13 1996-12-13 Bioresolution
GB9625972.6 1996-12-13
GBGB9712298.0A GB9712298D0 (en) 1997-06-12 1997-06-12 Crystallisation
GB9712298.0 1997-06-12
PCT/GB1997/003418 WO1998025902A1 (fr) 1996-12-13 1997-12-11 Preparation de threo-methylphenidate enrichi en un enantiomere

Publications (1)

Publication Number Publication Date
CA2272373A1 true CA2272373A1 (fr) 1998-06-18

Family

ID=26310627

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002272373A Abandoned CA2272373A1 (fr) 1996-12-13 1997-12-11 Preparation de threo-methylphenidate enrichi en un enantiomere

Country Status (9)

Country Link
EP (1) EP0948484A1 (fr)
JP (1) JP2001506621A (fr)
AU (1) AU7847098A (fr)
CA (1) CA2272373A1 (fr)
CZ (1) CZ206299A3 (fr)
HU (1) HUP0001604A3 (fr)
NO (1) NO992875L (fr)
PL (1) PL334136A1 (fr)
WO (1) WO1998025902A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6100401A (en) * 1998-04-20 2000-08-08 Novartris Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6162919A (en) * 1998-12-03 2000-12-19 Novartis Ag Process for preparing the d-threo isomer of methylphenidate hydrochloride
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
US6221883B1 (en) * 2000-04-12 2001-04-24 Ross Baldessarini Method of dopamine inhibition using l-threo-methylphenidate
DE60027282T2 (de) * 2000-06-17 2007-04-12 Pharmaquest Ltd., Hamilton Verwendung von l-threo-methylphenidate zur Herstellung eines Medikaments für die Behandlung von Depression
WO2004080959A2 (fr) * 2003-03-07 2004-09-23 Isp Investments Inc. Procede de preparation de dexmethylphenidate hydrochlorure
US7897777B2 (en) 2007-01-05 2011-03-01 Archimica, Inc. Process of enantiomeric resolution of D,L-(±)-threo-methylphenidate
WO2010128517A1 (fr) 2009-05-07 2010-11-11 Malladi Drugs & Pharmaceuticals Ltd. Procédé amélioré pour la préparation de chlorhydrate d'acide d-thréo-ritalinique par la résolution de l'acide dl-thréo-ritalinique au moyen d'un acide carboxylique chiral
JP5886869B2 (ja) 2010-12-17 2016-03-16 ローズ テクノロジーズ メチルフェニデート塩酸塩の低温合成
EP4011364B1 (fr) 2011-03-23 2023-12-13 Ironshore Pharmaceuticals & Development, Inc. Procédés et compositions pour le traitement de troubles du déficit de l'attention
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9233924B2 (en) 2014-03-11 2016-01-12 Ampac Fine Chemicals Llc Methods for preparing D-threo methylphenidate using diazomethane, and compositions thereof
US10081597B2 (en) 2014-06-27 2018-09-25 Embio Limited Process for preparation of dexmethylphenidate hydrochloride

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02190195A (ja) * 1989-01-19 1990-07-26 Rikagaku Kenkyusho 光学活性プロピオン酸エステル類化合物の製法
JPH02273196A (ja) * 1989-03-08 1990-11-07 Wisconsin Alumni Res Found ラセミ化合物の生体触媒分割のエナンチオ選択性の改良法
JP3431204B2 (ja) * 1993-04-22 2003-07-28 塩野義製薬株式会社 ノルボルナン型エステル・ヒドロラーゼ
BE1007297A3 (nl) * 1993-07-19 1995-05-09 Dsm Nv Werkwijze voor de bereiding van optisch aktieve alcoholen en esters, en alcoholen en esters toegepast en bereid in dergelijke werkwijzen.
DE4420751A1 (de) * 1994-06-15 1995-12-21 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Lactamen

Also Published As

Publication number Publication date
NO992875L (no) 1999-06-14
NO992875D0 (no) 1999-06-11
HUP0001604A2 (hu) 2000-10-28
PL334136A1 (en) 2000-02-14
JP2001506621A (ja) 2001-05-22
WO1998025902A1 (fr) 1998-06-18
HUP0001604A3 (en) 2003-03-28
CZ206299A3 (cs) 1999-09-15
AU7847098A (en) 1998-07-03
EP0948484A1 (fr) 1999-10-13

Similar Documents

Publication Publication Date Title
CA2272373A1 (fr) Preparation de threo-methylphenidate enrichi en un enantiomere
CA2141843A1 (fr) Methode de preparation de precurseurs de la paroxetine optiquement purs
US7164025B2 (en) Manufacture of single isomer methylphenidate
US20010018205A1 (en) Process for stereospecific hydrolysis of piperidinedione derivatives
Stein et al. Enzyme-catalyzed regioselective hydrolysis of aspartate diesters
EP0440723B1 (fr) Procede de preparation d'esters de glycidate optiquement actifs
EP0222561B1 (fr) Procédé de séparation enzymatique d'isomères optiquement actifs de 2-aminobutanol
EP1532146B1 (fr) Procede de preparation d'enantiomeres de derives d'indole-2,3-dione-3-oxime
JP4843813B2 (ja) 酵素を用いるＲ−体又はＳ−体のα−置換ヘテロサイクリックカルボン酸及びこれと反対鏡像の鏡像異性体のα−置換ヘテロサイクリックカルボン酸エステルの調製方法
US6153414A (en) Method for racemic biochemical resolution of CIS-and trans-pyprolopiperidine
JP4843812B2 (ja) 酵素を使用するラセミα−置換ヘテロ環式カルボン酸の光学分割方法
KR100368735B1 (ko) 효소를 이용한 Ｒ-폼 또는 Ｓ-폼의 α-치환헤테로싸이클릭 카르복실산의 제조 방법
EP0239122A2 (fr) Procédé de résolution enzymatique de 2-amino-1-alcanols racémiques
EP1280775A1 (fr) Tosylates de 4-(p-fluorophenyl)-piperidine-3-carbinols
US5929242A (en) Manufacture of levobupivacaine and analogues thereof from L-lysine
JP2612671B2 (ja) 光学活性なプロピオン酸エステルの製造法
JP5329973B2 (ja) リパーゼ触媒を用いるエナンチオ選択的アシル化とその後の硫酸による沈殿によって、ラセミ体の４−（１−アミノエチル）安息香酸メチルエステルから（ｒ）−および（ｓ）−４−（１−アンモニウムエチル）安息香酸メチルエステル硫酸塩を調製する方法
WO2007069841A1 (fr) Procede de preparation de cyclopropane carboxamide optiquement actif, et de ses derives
JPH0649005A (ja) ビニルグリシン（２−アミノ−３−ブテン酸）の簡単な製造方法および誘導体の簡便な分割
KR100617952B1 (ko) 광학활성 피리도 벤즈옥사진 유도체의 제조방법
EP1355882B1 (fr) Echafaudages chiraux et leur preparation
KR20010037656A (ko) 키랄 알릴 알콜의 제조방법
EP0908522A1 (fr) Procédé de préparation de 2-alkanol optiquement actif

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued